Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 80
- Registration Number
- NCT03555188
- Locations
- 🇬🇧
Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
🇬🇧Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
🇬🇧University Hospital of South Manchester, Manchester, United Kingdom
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Pharmacogenomics and Post-Operative Nausea and Vomiting
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 92
- Registration Number
- NCT03503292
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 130
- Registration Number
- NCT03478605
- Locations
- 🇷🇺
N.N. Blokhin Cancer Research Center, Moscow, Russian Federation
Post Operative Pain Control After Pediatric Hip Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03435692
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 83
- Registration Number
- NCT03435003
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?
- Conditions
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 46
- Registration Number
- NCT03262038
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 100
- Registration Number
- NCT03254459
- Locations
- 🇺🇸
Lotus Clinical Research, LLC, Pasadena, California, United States
🇺🇸Epic Medical Research, Murray, Utah, United States
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 110
- Registration Number
- NCT03239210
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸The Nathan S. Kline Institute for Psychiatric Research, New York, New York, United States
"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2019-08-20
- Target Recruit Count
- 240
- Registration Number
- NCT03219710
- Locations
- 🇮🇳
Dr Bra Irch, Aiims, New Delhi, New Delhi, Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.